Neurocrine Biosciences (NASDAQ:NBIX – Get Free Report) was upgraded by research analysts at StockNews.com from a “buy” rating ...

In this article, we will be taking a look at the 15 best biotech stocks to buy according to billionaires. Although biotech ...

M&T Bank Corp lifted its stake in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) by 23.4% in the fourth ...

SAN DIEGO, March 11, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will participate at the Stifel 2025 Virtual CNS Forum at 1:30 p.m. Eastern Time on Tuesday, March 18 ...

Topline data from Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis expected in the third quarter of 2025.Fourth positive DSMB ...

Tau silencing gene therapy VY1706 robustly reduced tau mRNA levels, with broad distribution, and was well-tolerated in NHP study; IND filing ...

Topline data from Phase 3 EFZO-FIT study of efzofitimod in pulmonary sarcoidosis expected in the third quarter of 2025. Fourth positive DSMB review for efzofitimod in Phase 3 EFZO-FIT study reinforces ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions.

Launched on 02/23/2016, the Janus Henderson Small/Mid Cap Growth Alpha ETF (JSMD) is a passively managed exchange traded fund designed to provide a broad exposure to the Small Cap Growth segment of ...

Q4 2024 Earnings Call Transcript March 13, 2025 aTyr Pharma, Inc. beats earnings expectations. Reported EPS is $-0.18, expectations were $-0.23. Operator: Good afternoon, ladies and gentlemen, and ...

Researchers have conducted the first national survey on public awareness and perceptions of food, health, and Food is ...

Biopharma companies require optimal clone yields to ensure maximum concentration and effectiveness of these therapeutic ...